ACA-话题@MedSci

#ACA#

226篇内容 | 3717人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1651979, encodeId=d41116519e973, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=FDA接受BMS在梗阻性肥厚性心肌病（oHCM）中使用Mavacamten的申请, objectType=article, longId=208823, objectId=6828208823c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6828208823c0, replyNumber=0, likeNumber=71, createdTime=2021-07-29, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6828208823c0, moduleTitle=FDA接受BMS在梗阻性肥厚性心肌病（oHCM）中使用Mavacamten的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6828208823c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651982, encodeId=baac16519820c, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=Lancet：Mavacamten可明显改善梗阻性肥厚型心肌病患者的健康状况, objectType=article, longId=211560, objectId=b35921156090, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b35921156090, replyNumber=0, likeNumber=53, createdTime=2022-02-08, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b35921156090, moduleTitle=Lancet：Mavacamten可明显改善梗阻性肥厚型心肌病患者的健康状况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b35921156090)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651990, encodeId=db0c16519909a, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=Lancet Oncol：慢性淋巴细胞白血病三联一线疗法：Acalabrutinib+Venetoclax+Obinutuzumab！, objectType=article, longId=217212, objectId=a44c21e21243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a44c21e21243, replyNumber=0, likeNumber=60, createdTime=2021-10-18, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a44c21e21243, moduleTitle=Lancet Oncol：慢性淋巴细胞白血病三联一线疗法：Acalabrutinib+Venetoclax+Obinutuzumab！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a44c21e21243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651984, encodeId=8f8c165198483, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=J Eur Acad Dermatol Venereol：参与治疗性患者教育的特异性皮炎的患儿特征, objectType=article, longId=214464, objectId=f9c32144640d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9c32144640d, replyNumber=0, likeNumber=65, createdTime=2021-12-31, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9c32144640d, moduleTitle=J Eur Acad Dermatol Venereol：参与治疗性患者教育的特异性皮炎的患儿特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9c32144640d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651995, encodeId=722516519953e, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究, objectType=article, longId=221205, objectId=3c79221205ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c79221205ea, replyNumber=0, likeNumber=57, createdTime=2022-01-09, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c79221205ea, moduleTitle=J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c79221205ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651985, encodeId=54cc16519859e, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=J Clin Oncol：Acalabrutinib和依鲁替尼用于CLL的长期疗效PK！, objectType=article, longId=214991, objectId=9fdb214991ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fdb214991ba, replyNumber=0, likeNumber=63, createdTime=2022-04-12, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fdb214991ba, moduleTitle=J Clin Oncol：Acalabrutinib和依鲁替尼用于CLL的长期疗效PK！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fdb214991ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651992, encodeId=b2b7165199240, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=J Eur Acad Dermatol Venereol：疫情之下，与个人防护设备有关的皮肤不良事件, objectType=article, longId=218776, objectId=e93a218e7629, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e93a218e7629, replyNumber=0, likeNumber=65, createdTime=2022-07-16, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e93a218e7629, moduleTitle=J Eur Acad Dermatol Venereol：疫情之下，与个人防护设备有关的皮肤不良事件, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e93a218e7629)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651981, encodeId=7b4b1651981f0, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=J Am Acad Dermatol：鲁索替尼乳膏治疗特异性皮炎的两项3期试验结果汇总, objectType=article, longId=211533, objectId=bdc621153385, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdc621153385, replyNumber=0, likeNumber=104, createdTime=2022-01-24, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdc621153385, moduleTitle=J Am Acad Dermatol：鲁索替尼乳膏治疗特异性皮炎的两项3期试验结果汇总, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdc621153385)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651989, encodeId=c99216519894a, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=JBMR:Odanacatib 对患有骨质疏松症的绝经后妇女骨结构和质量的影响, objectType=article, longId=216755, objectId=8362216e5512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8362216e5512, replyNumber=0, likeNumber=54, createdTime=2022-01-26, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8362216e5512, moduleTitle=JBMR:Odanacatib 对患有骨质疏松症的绝经后妇女骨结构和质量的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8362216e5512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651971, encodeId=177a16519e1e6, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=J Am Acad Dermatol：杜匹鲁单抗可有效治疗特应性皮炎, objectType=article, longId=203231, objectId=83c12032317e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83c12032317e, replyNumber=0, likeNumber=60, createdTime=2021-04-17, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83c12032317e, moduleTitle=J Am Acad Dermatol：杜匹鲁单抗可有效治疗特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83c12032317e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651973, encodeId=7fd816519e375, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=Clin Cancer Res：CEACAM5的调控及抗CEACAM5-SN38抗体-药物结合物在神经内分泌前列腺癌中的治疗效果 , objectType=article, longId=204057, objectId=4ed120405e9f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ed120405e9f, replyNumber=0, likeNumber=77, createdTime=2021-02-08, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ed120405e9f, moduleTitle=Clin Cancer Res：CEACAM5的调控及抗CEACAM5-SN38抗体-药物结合物在神经内分泌前列腺癌中的治疗效果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ed120405e9f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651980, encodeId=e1511651980ea, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=J Am Acad Dermatol：阿普斯特可有效治疗中重度头皮银屑病, objectType=article, longId=210774, objectId=7d74210e742f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d74210e742f, replyNumber=0, likeNumber=63, createdTime=2021-09-29, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d74210e742f, moduleTitle=J Am Acad Dermatol：阿普斯特可有效治疗中重度头皮银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d74210e742f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651976, encodeId=504e16519e63e, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=欧洲接受CAR-T疗法Ciltacabtagene Autoleucel（Cilta-cel）的加速评估，以治疗多发性骨髓瘤, objectType=article, longId=206689, objectId=8a6220668996, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a6220668996, replyNumber=0, likeNumber=63, createdTime=2021-11-02, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a6220668996, moduleTitle=欧洲接受CAR-T疗法Ciltacabtagene Autoleucel（Cilta-cel）的加速评估，以治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a6220668996)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651974, encodeId=aedd16519e415, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=NICE支持Calquence（acalabrutinib）治疗慢性淋巴细胞白血病, objectType=article, longId=204332, objectId=25ac2043325e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25ac2043325e, replyNumber=0, likeNumber=78, createdTime=2021-07-29, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25ac2043325e, moduleTitle=NICE支持Calquence（acalabrutinib）治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25ac2043325e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651967, encodeId=c265165196ee2, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=FDA批准KALYDECO（ivacaftor）作为也是**的CFTR调节剂治疗囊性纤维化患儿, objectType=article, longId=201255, objectId=b45e20125596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b45e20125596, replyNumber=0, likeNumber=84, createdTime=2021-01-14, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b45e20125596, moduleTitle=FDA批准KALYDECO（ivacaftor）作为也是**的CFTR调节剂治疗囊性纤维化患儿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b45e20125596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651968, encodeId=7ee3165196848, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=Clin Cancer Res：新型抗体-药物耦联剂SAR408701治疗CEACAM5阳性上皮肿瘤的活性, objectType=article, longId=202096, objectId=825120209604, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=825120209604, replyNumber=0, likeNumber=64, createdTime=2021-04-06, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=825120209604, moduleTitle=Clin Cancer Res：新型抗体-药物耦联剂SAR408701治疗CEACAM5阳性上皮肿瘤的活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=825120209604)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651964, encodeId=4af0165196443, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=吉利德科学：长效HIV-1衣壳抑制剂Lenacapavir（GS-6207）临床表现良好, objectType=article, longId=197123, objectId=dc3519e123a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc3519e123a3, replyNumber=0, likeNumber=63, createdTime=2021-01-01, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc3519e123a3, moduleTitle=吉利德科学：长效HIV-1衣壳抑制剂Lenacapavir（GS-6207）临床表现良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc3519e123a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651969, encodeId=42e01651969d6, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=Br J Cancer：LncRNA HOTAIR通过靶向hepaCAM促进前列腺癌的侵袭和转移, objectType=article, longId=202254, objectId=d2c520225459, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2c520225459, replyNumber=0, likeNumber=62, createdTime=2021-05-22, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2c520225459, moduleTitle=Br J Cancer：LncRNA HOTAIR通过靶向hepaCAM促进前列腺癌的侵袭和转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2c520225459)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651965, encodeId=1f0416519657d, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=Lancet：心肌肌球蛋白抑制剂Mavacamten治疗梗阻性肥厚型心肌病！, objectType=article, longId=200122, objectId=01d820012261, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01d820012261, replyNumber=0, likeNumber=84, createdTime=2020-10-06, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01d820012261, moduleTitle=Lancet：心肌肌球蛋白抑制剂Mavacamten治疗梗阻性肥厚型心肌病！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01d820012261)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1651977, encodeId=02bf16519e776, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, objectTitle=Lancet Respir Med：Tezacaftor-iVacaftor治疗携带CFTR Phe508del突变的囊性纤维化患者的长期预后, objectType=article, longId=207122, objectId=8d1120e122ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d1120e122ef, replyNumber=0, likeNumber=59, createdTime=2021-11-27, rootId=0, userName=lishizhe, userId=843c24278901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d1120e122ef, moduleTitle=Lancet Respir Med：Tezacaftor-iVacaftor治疗携带CFTR Phe508del突变的囊性纤维化患者的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d1120e122ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ACA

2020-05-29

lishizhe (审核中...)

前往app查看评论内容

#ACA#

FDA接受BMS在梗阻性肥厚性心肌病（oHCM）中使用Mavacamten的申请

2021-07-29

lishizhe (审核中...)

前往app查看评论内容

#ACA#

Lancet：Mavacamten可明显改善梗阻性肥厚型心肌病患者的健康状况

2022-02-08

lishizhe (审核中...)

前往app查看评论内容

#ACA#

Lancet Oncol：慢性淋巴细胞白血病三联一线疗法：Acalabrutinib+Venetoclax+Obinutuzumab！

2021-10-18

lishizhe (审核中...)

前往app查看评论内容

#ACA#

J Eur Acad Dermatol Venereol：参与治疗性患者教育的特异性皮炎的患儿特征

2021-12-31

lishizhe (审核中...)

前往app查看评论内容

#ACA#

J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究

2022-01-09

lishizhe (审核中...)

前往app查看评论内容

#ACA#

J Clin Oncol：Acalabrutinib和依鲁替尼用于CLL的长期疗效PK！

2022-04-12

lishizhe (审核中...)

前往app查看评论内容

#ACA#

J Eur Acad Dermatol Venereol：疫情之下，与个人防护设备有关的皮肤不良事件

2022-07-16

lishizhe (审核中...)

前往app查看评论内容

#ACA#

J Am Acad Dermatol：鲁索替尼乳膏治疗特异性皮炎的两项3期试验结果汇总

2022-01-24

lishizhe (审核中...)

前往app查看评论内容

#ACA#

JBMR:Odanacatib 对患有骨质疏松症的绝经后妇女骨结构和质量的影响

2022-01-26

lishizhe (审核中...)

前往app查看评论内容

#ACA#

J Am Acad Dermatol：杜匹鲁单抗可有效治疗特应性皮炎

2021-04-17

lishizhe (审核中...)

前往app查看评论内容

#ACA#

Clin Cancer Res：CEACAM5的调控及抗CEACAM5-SN38抗体-药物结合物在神经内分泌前列腺癌中的治疗效果

2021-02-08

lishizhe (审核中...)

前往app查看评论内容

#ACA#

J Am Acad Dermatol：阿普斯特可有效治疗中重度头皮银屑病

2021-09-29

lishizhe (审核中...)

前往app查看评论内容

#ACA#

欧洲接受CAR-T疗法Ciltacabtagene Autoleucel（Cilta-cel）的加速评估，以治疗多发性骨髓瘤

2021-11-02

lishizhe (审核中...)

前往app查看评论内容

#ACA#

NICE支持Calquence（acalabrutinib）治疗慢性淋巴细胞白血病

2021-07-29

lishizhe (审核中...)

前往app查看评论内容

#ACA#

FDA批准KALYDECO（ivacaftor）作为也是**的CFTR调节剂治疗囊性纤维化患儿

2021-01-14

lishizhe (审核中...)

前往app查看评论内容

#ACA#

Clin Cancer Res：新型抗体-药物耦联剂SAR408701治疗CEACAM5阳性上皮肿瘤的活性

2021-04-06

lishizhe (审核中...)

前往app查看评论内容

#ACA#

吉利德科学：长效HIV-1衣壳抑制剂Lenacapavir（GS-6207）临床表现良好

2021-01-01

lishizhe (审核中...)

前往app查看评论内容

#ACA#

Br J Cancer：LncRNA HOTAIR通过靶向hepaCAM促进前列腺癌的侵袭和转移

2021-05-22

lishizhe (审核中...)

前往app查看评论内容

#ACA#

Lancet：心肌肌球蛋白抑制剂Mavacamten治疗梗阻性肥厚型心肌病！

2020-10-06

lishizhe (审核中...)

前往app查看评论内容

#ACA#

Lancet Respir Med：Tezacaftor-iVacaftor治疗携带CFTR Phe508del突变的囊性纤维化患者的长期预后

2021-11-27

科室
- - 订阅+
  - 更多科室
工具
服务